The thesis is simple: As societies get wealthier, metabolic disease becomes more common.
Obesity and type 2 diabetes are rising across the developed world and increasingly in emerging markets. Lilly already owns the dominant position in the most effective class of drugs addressing this.
Full details on position sizing & the monthly add are for paid subscribers.
Now is a good time to join.